Tags : Pherin

VistaGen Therapeutics Acquires WW Rights for Pherin’s PH94B nasal spray

Shots: Pherin will receive $2.25M of unregistered common stock (1,630,435 unregistered shares) from Vista VistaGen has rights to commercialize and develop PH94B nasal spray (expected to enter in P-III in H1’19) as a PRN treatment for SAD, in addition to an option to acquire Pherin’s CNS neuropsychiatry-focused product currently under P-II The main focus of […]Read More